OBJECTIVES: To evaluate the clinical effectiveness of sorafenib and sunitinib in metastatic renal cell carcinoma (RCC) by using indirect comparison meta-analysis. METHODS: Systematic literature search of Medline, Embase, Cochrane controlled trials register. All randomized clinical trials of sorafenib or sunitinib versus interferon alfa for treating metastatic renal-cell carcinoma were included. Study selection, data extraction and quality assessment were performed by two reviewers with disagreements being resolved by consensus. The effects of sorafenib and sunitinib on progression-free survival were compared indirectly using indirect treatment comparison program, with interferon alfa (IFN) as a common comparator. RESULTS: Two studies were included. Median progression-free survival was prolonged with the treatment of sunitinib (11 months) compared to interferon alfa (5 months). For the comparison of sorafenib and interferon-alfa, the median progression-free survival was similar (median PFS: 5.7 months vs. 5.6 months). Indirect comparison suggests that sunitinib is not superior to sorafenib for prolongation of progress free survival (hazard ratio 0.37; 95% CI: 0.236-0.58, P = 0.0189). CONCLUSIONS: There is no signifi cant evidence to suggest that treatment with sunitinib has clinical advantages over treatment with sorafenib in patients with metastatic RCC. OBJECTIVES: To determine whether the association between the different dosage of hormone replacement therapy (HRT) and the incidence of breast cancer (BC) in postmenopausal women with HRT formulation. METHODS: Patients who had at least one outpatient visit for postmenopausal syndrome (ICD-9-CM code 627) with estrogen prescription in Taiwan National Health Insurance (NHI) claims database during 1999-2006 were identifi ed as the study cases. There were 883,052 women identifi ed from the dataset. The index date was defi ned as the date of the fi rst menopausal visit with estrogen prescription during the study period. To identify any BC events, each case was tracked from the index date until December 31, 2006 or death, whichever came fi rst. Women without events were censored on December 31, 2006. Survival analysis was performed to assess whether cumulative estrogen dosage and combined progesterone were independent risk factors of BC. RESULTS: A total of 5524 cases of BC were identifi ed during the study period. Women with higher dosage of estrogen had signifi cantly higher risk of BC than women with lower dosage (HR = 2.23; P < 0.0001). The risk of BC was even higher when progesterone was combined with estrogen (HR = 1.08; P = 0.036). Women aged 60-69 (HR = 0.87, P = 0.002) and >70 (HR = 0.66, P < 0.0001) had lower risk of BC, compared with women aged <60. Women living in the northern part of Taiwan and in areas with higher urbanization level had higher risk of BC, compared with their counterparts. CONCLUSIONS: Hormone replacement therapy in postmenopausal women seemed to be associated with an increased risk of BC.
This study is to investigate the characteristics on incidence of stomach, lung, liver, breast and kidney cancer, and to estimate the total number of new cancer cases in China in 2004. METHODS: Incidence data were collected through 37 local cancer registries across 19 provinces and autonomous regions in China, 2004 . Data were classifi ed by ICD-10 and processed according to international cancer registration guidelines. The number of new cancer cases was estimated by local cancer registry data, residence population in the corresponding areas, and the population of China in 2004. RESULTS: Registry data covered a population of 57,698,672 residents, accounting for 4.44% of Chinese population in 2004. There were 73,552 new cancer cases registered, with world age-adjusted incidence by cancer type ranging from 2.69 per 100,000 to 31.55 per 100,000. Overall, lung cancer was highest in incidence rate, followed by cancer of stomach, liver and breast, while kidney cancer accounted for a relatively small proportion. Cancer among urban residents by incidence per 100,000 was lung (33.19), stomach (18.22), breast (16.52), liver (15.83) and kidney (3.32), while in rural residents was stomach (40.35), liver (28.66), lung (26.30), breast (6.19), and kidney (0.68). Cancer in men by incidence per 100,000 was lung (44.21), stomach (33.32), liver (28.94) and kidney (3.50), while in women was breast (27.76), lung (19.98), stomach (14.06), liver (8.97) and kidney (1.94). Total cancer incidence was estimated 30,571,904 in china in 2004. Estimation of cancer incidence of stomach, lung, liver, breast and kidney was 10, 609,682, 7,335,176, 5,927,478, 2,492,148, and 376,927, respectively . CONCLUSIONS: Cancer incidence rates vary by region and gender in China. The overall burden of cancer is heavy and more attention should be paid to cancer prevention and control.
CANCER -Cost Studies

PCN8 IDENTIFYING KEY PROCEDURES IN HEPATOCELLULAR CARCINOMA PATIENTS WITH HIGHEST PAYER BUDGET IMPACT IN A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES
Tsong W 1 , Singer ME 2 , Ray S 1 1 Abbott Laboratories, Abbott Park, IL, USA; 2 Case Western Reserve University School of Medicine, Cleveland, OH, USA OBJECTIVES: Although hepatocellular carcinoma (HCC) is a highly prevalent disease in East Asia with a growing incidence in the US, there is a limited understanding of health-care procedures and their economic impact. This study identifi es the procedures with the highest payer budget impact in a commercially insured US population. METHODS: The MEDSTAT insurance claims database (January 1, 2000-December 31, 2008) was used to identify a cohort of patients with > = 1 HCC claim (index = fi rst claim), age > = 18, and no other cancer diagnoses. For each procedure code, all payments (2009 USD) were summed across the cohort and divided by the total patientmonths to estimate the per patient-month (PM) cost. The PM costs were ranked to identify procedures with the highest payer budget impact. The proportion of patients utilizing each procedure was calculated to evaluate whether PM costs were driven by a minority of patients. RESULTS: The study sample included 2927 patients: mean age 50.4 years, 57% male, and median 9 months follow-up. The inpatient procedures with the highest budget impact were: liver transplant and/or intestinal transplant ($526/ PM, 4.6% of patients), tracheostomy with mechanical ventilation ($204/PM, 0.2%), disorders of liver except malignancy/cirrhosis/alcoholic hepatitis ($96/PM, 5.1%). For hospital outpatient procedures, they were: magnetic resonance imaging (MRI) of the abdomen ($18/PM, 15%), computed tomography of abdomen ($13/PM, 17%), and transcatheter occlusion/embolization ($8/PM, 4%). For offi ce outpatient procedures, they were: low complexity visits ($26/PM, 70%), moderate complexity visits ($18/ PM, 18%), and MRI of abdomen ($8/PM, 7%). Patients with > = 1 sorafenib prescription (<2% of cohort) had a minimal impact on the results. CONCLUSIONS: The key procedures with the highest budget impact appear to be related to both cancer and liver disease. These costs may be reduced with improved anticancer therapy which provides better cancer control and reduces the exacerbation of liver disease from tumor growth.
PCN9 FIRST YEAR MEDICAL CARE COSTS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN A MEDICAID POPULATION
Tsong W 1 , White LA 2 , Ray S 1 1 Abbott Laboratories, Abbott Park, IL, USA; 2 Boston Health Economics, Waltham, MA, USA OBJECTIVES: Although hepatocellular carcinoma (HCC) is highly prevalent in East Asia with a growing incidence in the United States, the economic impact of the disease has not been extensively studied. This study compares medical costs of HCC patients in the fi rst year after diagnosis with those of non-cancer controls. METHODS: A Medicaid database (July 1, 2001 -June 30, 2007 was used to identify cases with > = 1 HCC claim, > = 1 HCC post-index claim, and no other cancers. Controls were matched on age, sex, and race. Costs (2008 USD) for medical care services (inpatient, outpatient, emergency room [ER], long-term care [home health, nursing home, hospice]) were analyzed as fi rst-year costs and follow-up adjusted costs (per-patientper-month [PPPM]). All costs were compared using rank sum tests. RESULTS: The study identifi ed 126 HCC cases and 126 controls: mean age 49 years, 51% male, mean follow-up months: 9.2 cases/11.9 controls, and deaths: 29.4% cases/1.6% controls. First-year costs were 1.5 to 8 times higher in cases versus controls (long-term care $3752 vs. $2554, ER $126 vs. $51, outpatient $4143 vs. $1412, inpatient $12,425 vs. $1595, all with P < 0.012). PPPM costs were 3 to 27 times higher in cases versus controls (long-term care $626 vs. $233, outpatient $884 vs. $119, ER $34 vs. $4, inpatient $3738 vs. $139, all with P < 0.001). Total costs were two times higher for HCC cases in the fi rst year ($29,795 vs. $13,151, P < 0.001) and six times higher as PPPM ($6376 vs. $1125, P < 0.001). No patients had a sorafenib prescription. CONCLUSIONS: First-year medical care costs were substantially higher for the HCC patients, and even higher when adjusted for follow-up on a PPPM basis. Future therapies that improve survival and disease control may enable payers to reduce monthly costs, and use the savings to treat other patients.
PCN10 ESTIMATION OF THE HEALTH AND COST BURDEN OF HPV-RELATED DISEASES IN THAILAND
Termrungruanglert W 1 , Havanond P 1 , Khemapech N 1 , Lertmaharit S 1 , Pongpanich S 1 , Khorprasert C 1 , Kitsiripornchai S 2 , Jirakorbchaipong P 2 , Taneepanichskul S 1 1 Chulalongkorn University, Bangkok, Thailand; 2 MSD (Thailand) Ltd., Bangkok, Thailand BACKGROUND: Cervical cancer is the fi rst leading female cancer, especially, in developing countries. The two available HPV vaccines protect against HPV types 16/18 responsible for majority of cervical cancer. The quadrivalent vaccine also protects against HPV types 6/11 that cause majority of genital warts. It is important to examine health and cost burden of HPV-related diseases to understand the potential impact of introducing HPV vaccine. OBJECTIVES: We aimed to evaluate the longterm health and cost burden associated with cervical cancer, cervical intraepitherial neoplasia (CIN) and genital warts from health-care provider perspective in Thailand.
METHODS:
We developed a state-transition Markov model to simulate the epidemiology of stages of cervical cancer, CIN and genital warts in a hypothetical cohort of 100,000 12-year-old girls. Costs included diagnosis and treatment costs of HPV related diseases. Probabilities at each chance node in the model were derived from the Thailand health-care context. RESULTS: The highest incidence of CIN and genital warts was observed among women aged 20-30 years. For cervical cancer, the highest incidence was observed among women aged 45-55 years. Death rate was estimated at 2%, 8%, 84%, and 94% for cervical cancer stage IA1, IA2-IIA, IIB-IVA, and IVB, respectively. The estimated mean direct cost per patient with cervical cancer stage IA1, IA2-IIA, IIB-IVA, IVB, CIN1, CIN2/3 and genital warts were US$1277, US$3020, US$12,506, US$10,019, US$167, US$1551, and US$111, respectively. The overall lifetime costs were estimated at US$26.7 million for a cohort of 100,000 women, which corresponded to approximately US$132.0 million for the current entire cohort of 12-year-old girls in Thailand. CONCLUSIONS: HPV-related diseases impose signifi cant health and cost burden in Thailand. The potential impact on HPV-related diseases of a national immunization program with HPV vaccine should be examined to inform the policy discussions around the HPV vaccination program in Thailand.
PCN11
PREVENTION OF OXALIPLATIN HYPERSENSITIVITY REACTION AND COST SAVING
Huang SF, Chen CH, Chan AL Chi Mei Medical Center, Tainan, Taiwan OBJECTIVES: Hypersensitivity reactions have been reported in Oxaliplatin for the treatment of advanced colorectal cancer (mCRC). The reported incidence of hypersensitivity reactions (HSRs) is approximately 12%, with 1-2% of patients developing grade 3 or 4 in severity which may postpone length of stay and incurred extra cost for the treatment of hypersensitivity reactions. METHODS: This is a retrospective observational study. Medical records of hospitalized patients with mCRC, who treated with FOLFOX regimen and occurred mild to severe HSRs were identifi ed and reviewed by oncology pharmacist from January 2004 to February 2010. Direct medical cost for the treatment of HSRs and the extra days of hospitalization were calculated. We compared the difference of direct medical cost for patients whose oxaliplatin was discontinued (group A) and those oxaliplatin was continued (group B) for treating mCRC after the computer detected patients' allergy and the signal was appeared on the screen of physician-order-entry-system. Student t test was used for data analysis. RESULTS: A total of 442 patients with the diagnosis of mCRC and had reported moderate to severe HSRs during the treatment of FOLFOX regimen through our computerized decision supporting system (patients allergy history alert system) were included in this study. Twenty-four of 442 patients reported mild to severe hypersensitivity reactions caused by oxaliplatin. The total direct medical costs for 24 patients were NT$864,352 dollars. The direct medical cost to manage HRSs in group A was higher than that in group B. CONCLUSIONS: Oxaliplatin induced severe hypersensitivity reaction is scare, but it may cause an extra direct medical costs if it is appearance. To develop a computerized alert signal is helpful and is likely to save costs.
PCN12
COST-EFFECTIVENESS OF THE ONCOTYPE DX® ASSAY IN AUSTRALIA: AN EXPLORATORY ANALYSIS
O'Leary B 1 , Foteff C 2 , Byron K 3 , Chang C 4 , Chao C 4 , Ng C 5 , Skrzypczak S 4 1 Covance Pty Ltd, North Ryde, NSW, Australia; 2 Covance Pty Ltd, North Ryde, NSW, Australia; 3 Gribbles Pathology, Clayton, VIC, Australia; 4 Genomic Health, Inc., Redwood City, CA, USA; 5 Genomic Health, Inc., Hong Kong, HKSAR, Hong Kong OBJECTIVES: Oncotype DX is a molecular diagnostic assay that measures quantitative expression of 21 genes within a breast tumor sample. The result is reported as a recurrence score (RS) that correlates with the risk of 10-year recurrence. The potential cost impact on chemotherapy treatment and an exploratory cost utility analysis were undertaken from the Australian health-care system perspective. METHODS: Input on the proportion of patients treated with chemotherapy and treatment regimens were obtained from an expert panel and a supplementary survey of Australian clinicians (oncologists and surgeons, n = 12). Data on the proportion of patients who would forgo chemotherapy based on knowledge of the RS and the incidence and cost of adverse events were obtained from published literature. RESULTS: The clinician input indicated that 33% of node negative and 84% of node positive women receive adjuvant chemotherapy on average. The most common treatments for node-negative patients were AC (anthracycline and cyclophosphamide) (77%) and FEC100 (fl uorouracil, epirubicin and cyclophosphamide) (16%) and for node-positive patients FEC-D (FEC plus docetaxel) (54%), AC + paclitaxel (26%) and TAC (docetaxel plus AC) (14%). Published switch rates away from chemotherapy are 20% for node negative and 24% for node positive patients. The cost saving due to a reduction in chemotherapy was estimated to be A$2264 per woman tested. After consideration for the cost of the assay (A$4200) and a published utility rate of 0.5, a A$/QALY gain was estimated at A$9986. CONCLUSIONS: Knowledge of the Oncotype DX RS has a cost-offset due to the reduction in chemotherapy and is likely to be cost-effective. These benefi ts refl ect the quality of life and survival benefi ts of a more targeted approach to treatment decision-making. Further analysis is warranted to include the potential costs of relapse avoided by use of the assay and any patient indirect costs in Australia.
